Last reviewed · How we verify

Viral load driven treatment interruption

Hospital Clinic of Barcelona · FDA-approved active Small molecule

A treatment strategy that interrupts antiretroviral therapy based on viral load measurements to allow structured breaks in continuous HIV medication.

A treatment strategy that interrupts antiretroviral therapy based on viral load measurements to allow structured breaks in continuous HIV medication. Used for HIV-1 infection (treatment interruption strategy).

At a glance

Generic nameViral load driven treatment interruption
SponsorHospital Clinic of Barcelona
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Viral load-driven treatment interruption (VDTI) is a therapeutic strategy rather than a drug itself, involving periodic cessation of antiretroviral therapy guided by CD4 count and viral load thresholds. The approach aims to reduce long-term medication exposure and associated toxicities while maintaining immune control through structured interruption cycles. This strategy was investigated primarily in the early-to-mid 2000s as an alternative to continuous antiretroviral therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: